London, UK (PRWEB) September 20, 2012
Over the next decade, the cancer diagnostics market is predicted to really be an exciting, dynamic and rapidly evolving field worldwide. Expected key technological breakthroughs will enable to identify human cancer predisposition genes, detect and diagnose specific tumors, and monitor the biological response to cancer treatment. The rise in the elderly population will further compound the soaring demand for malignancy assays and the market’s explosive growth from pole to pole.
New research report “Analysis of the World Cancer Diagnostics Market: Sales Forecasts by Country and Strategic Profiles of Leading Suppliers” worked out by Venture Planning Group (VPG) is designed to provide estimates of the number of laboratories performing cancer tests, as well as test volume and sales forecasts by country. Additionally, the study carries out strategic reviews of the top current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
The key companies discussed include but are not limited to: Abbott, AdnaGen, Arca, Beckman Coulter/Danaher, Becton Dickinson, Biomedical Diagnostics, Bio-Rad, Cepheid, Correlogic Systems, Dako, Decode, Diadexus, Enterix, Enzo, Biochem, Epigenomics, Fujirebio, Gen-Probe, OncoLab, Takara Bio, Wako Pure Chemicals, Zila.
Title: Analysis of the World Cancer Diagnostics Market: Sales Forecasts by Country and Strategic Profiles of Leading Suppliers
Published: September, 2012
Price: US$ 3,500.00
More Medicine, Pharmaсeuticals & Biotechnology Market Reports by VPG Include:
More new market research reports by the publisher can be found at VPG page.